尿激酶、重组链激酶和纤溶酶在治疗下肢深静脉血栓中的疗效比较  

THE CLINICAL EFFECT OF UROKINASE,RECOMBINANT STREPTOKINASE AND FIBRINOGENASE TREATING LOWER LIMBS OF DEEP VEIN THROMBOSIS

作　　者：金志宏[1] 谢晓亮[1] 高占峰[1] 刘波[1] 

机构地区：[1]内蒙古医学院附属医院血管外科,内蒙古呼和浩特010050

出　　处：《内蒙古医学院学报》2012年第1期56-58,64,共4页Acta Academiae Medicinae Neimongol

摘　　要：目的:比较纤溶酶、尿激酶、重组链激酶在治疗下肢深静脉血栓中的临床疗效。方法:选取下肢深静脉血栓病人123例,分为三组,其中尿激酶治疗组50例,重组链激酶治疗组30例,纤溶酶治疗组43例。我们采取相同的治疗方案,每日测量患肢周径,每3d抽血检验凝血四项,D-二聚体,血常规检查。疗程分别为尿激酶5～7d,重组链激酶组4～5d,纤溶酶组约7～10d。结果:尿激酶组与重组链激酶组治疗临床有效率相近,无显著差异(P>0.05),与纤溶酶组比较有显著差异(P<0.05)。结论:三种药物溶栓效果相同,但尿激酶、重组链激酶治疗深静脉血栓优于纤溶酶。Objective：To compare the clinical effect of using fibrinogenase,urokinase and recombinant streptokinase in the treatment of deep vein thrombosis.Methods：Clinical analysis of 123 cases of pactients with deep vein thrombosis,were divided into urokinawe group（n=50）,recombinant streptokinase group（n=30）,fibrinogenase group（n=43）.We take the same treatment,Daily measurement of limb circumference,Coagulation blood tests,D-dimer,Blood routine examination every three days.Urokinase treatment was 5~7 days,4~5 days of recombinant streptokinase group,group type fibrinogenase about 7-10 days.Results：Recombinant streptokinase,urokinase group and clinical effective similar to the treatment group,no significant difference（P〉0.05）,compared with fibrinogenase were significantly different（P〈0.05）.Conclusion：The three drugs can achieve thrombolysis effect,but the effect of urokinase,recombinant streptokinase treatment were excellenter than fibrinogenase group.

关 键 词：下肢深静脉血栓 尿激酶 重组链激酶 纤溶酶 临床疗效 

分 类 号：R543.6[医药卫生—心血管疾病]